Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes.

@article{Dunn2011SelectiveMO,
  title={Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes.},
  author={Fredrick L. Dunn and Linda Slanec Higgins and Jill O Fredrickson and Alex M Depaoli},
  journal={Journal of diabetes and its complications},
  year={2011},
  volume={25 3},
  pages={151-8}
}
OBJECTIVE INT131 besylate is a potent non-thiazolidinedione selective peroxisome proliferator-activated receptor γ (PPARγ) modulator (SPPARM) designed to improve insulin sensitivity and glucose metabolism while minimizing the side effects of full agonist thiazolidinediones. This study was conducted to determine short-term efficacy and safety of INT131 besylate in patients with Type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS This was a 4-week randomized, double-blind, placebo… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

INT 131 : a selective modulator of PPAR γ

  • A. Motani, Z. Wang, +9 authors Y. Li
  • J Mol Biol
  • 2009
Highly Influential
8 Excerpts

Thiazolidinediones

  • H. Yki-Javinen
  • New Engl J Med, 351, 1106−1118.
  • 2004
Highly Influential
3 Excerpts

INT 131 : a selective PPAR γ modulator ( SPPARM ) significantly lowers glucose without typical thiazolidinedione ( TZD ) side effects in patients with type 2

  • A. M. DePaoli, F. Dunn, J. Fredrickson, L. Higgins
  • DIABETES
  • 2009
2 Excerpts

INT131: a selective PPARγ modulator (SPPARM) significantly lowers glucose without typical thiazolidinedione (TZD) side effects in patients with type 2 diabetes. Diabetes, 59(S1), A31−2

  • A. M. DePaoli, F. Dunn, J. Fredrickson, L. Higgins
  • 2009
3 Excerpts

Impact of INT 131 , a selective PPAR γ modulator ( SPPARM ) on glycemic control in patients with type 2 diabetes in a 24 week phase 2 b study

  • A. M. DePaoli, R. R. Henry, F. L. Dunn, P. C. Pakele, C. S. Mantzoros
  • 2009
2 Excerpts

Impact of INT131, a selective PPARγ modulator (SPPARM) on glycemic control in patients with type 2 diabetes in a 24 week phase 2b study. Diabetologia, 52(S1), S342

  • A. M. DePaoli, R. R. Henry, F. L. Dunn, P. C. Pakele, C. S. Mantzoros, L. S. Higgins
  • 2009
2 Excerpts

INT 131 , a nonTZD selective PPAR γ modulator ( SPPARM ) , does not cause toxicities typical of TZD full PPAR γ agonists following 6 - month high dose treatment of rats or monkeys

  • A. M. DePaoli, L. S. Higgins
  • Diabetologia
  • 2008
2 Excerpts

INT 131 : a selective PPAR γ modulator ( SPPARM ) for type 2 diabetes mellitus

  • F. Dunn, L. Higgins, A. DePaoli
  • 2008

Similar Papers

Loading similar papers…